Revance Therapeutics Inc. (RVNC) CEO L Daniel Browne Sells 12,000 Shares
Revance Therapeutics Inc. (NASDAQ:RVNC) CEO L Daniel Browne sold 12,000 shares of the firm’s stock in a transaction on Friday, November 25th. The shares were sold at an average price of $17.92, for a total transaction of $215,040.00. Following the sale, the chief executive officer now owns 208,449 shares in the company, valued at $3,735,406.08. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.
L Daniel Browne also recently made the following trade(s):
- On Wednesday, October 26th, L Daniel Browne sold 12,000 shares of Revance Therapeutics stock. The shares were sold at an average price of $14.85, for a total transaction of $178,200.00.
Shares of Revance Therapeutics Inc. (NASDAQ:RVNC) traded down 0.56% during mid-day trading on Monday, reaching $17.90. 8,760 shares of the company’s stock were exchanged. The company’s 50 day moving average is $15.74 and its 200 day moving average is $15.48. Revance Therapeutics Inc. has a 1-year low of $12.35 and a 1-year high of $40.40. The stock’s market capitalization is $510.42 million.
Revance Therapeutics (NASDAQ:RVNC) last released its earnings results on Thursday, November 3rd. The biopharmaceutical company reported ($0.64) earnings per share for the quarter, topping the consensus estimate of ($0.89) by $0.25. Revance Therapeutics had a negative net margin of 28,187.33% and a negative return on equity of 37.31%. During the same quarter in the prior year, the firm posted ($0.81) EPS. Equities research analysts anticipate that Revance Therapeutics Inc. will post ($3.21) EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This article was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this article on another website, it was copied illegally and reposted in violation of international trademark & copyright law. The legal version of this article can be read at https://www.thecerbatgem.com/2016/11/28/revance-therapeutics-inc-rvnc-ceo-l-daniel-browne-sells-12000-shares.html.
Several analysts have recently commented on the stock. Zacks Investment Research downgraded shares of Revance Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, August 17th. Brean Capital restated a “hold” rating on shares of Revance Therapeutics in a research report on Friday, August 5th. Two equities research analysts have rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $36.37.
Several hedge funds have recently added to or reduced their stakes in RVNC. BlackRock Group LTD increased its stake in Revance Therapeutics by 4.3% in the third quarter. BlackRock Group LTD now owns 6,398 shares of the biopharmaceutical company’s stock valued at $104,000 after buying an additional 261 shares during the period. BlackRock Advisors LLC increased its stake in Revance Therapeutics by 15.8% in the second quarter. BlackRock Advisors LLC now owns 9,802 shares of the biopharmaceutical company’s stock valued at $133,000 after buying an additional 1,338 shares during the period. FineMark National Bank & Trust increased its stake in Revance Therapeutics by 750.0% in the third quarter. FineMark National Bank & Trust now owns 8,500 shares of the biopharmaceutical company’s stock valued at $138,000 after buying an additional 7,500 shares during the period. Rothschild Asset Management Inc. acquired a new stake in Revance Therapeutics during the second quarter valued at approximately $143,000. Finally, American International Group Inc. increased its stake in Revance Therapeutics by 10.9% in the second quarter. American International Group Inc. now owns 11,769 shares of the biopharmaceutical company’s stock valued at $160,000 after buying an additional 1,161 shares during the period.
Revance Therapeutics Company Profile
Revance Therapeutics, Inc is a biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its TransMTS technology enables delivery of botulinum toxin type A through investigational drug product candidates, including DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical, and DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable.
Receive News & Stock Ratings for Revance Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics Inc. and related stocks with our FREE daily email newsletter.